Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
278 articles about Atara Biotherapeutics, Inc.
-
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
4/5/2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
3/28/2024
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.
-
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
2/29/2024
Atara Biotherapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ATA3219.
-
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
2/28/2024
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PST / 9:10 a.m. EST.
-
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
2/14/2024
Atara Biotherapeutics, Inc. today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]).
-
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
1/31/2024
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories announced that data from the pivotal Phase 3 ALLELE study of tab-cel, approved in the European Union in adults and children two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease following solid organ transplant or hematopoietic cell transplant, were published for the first time online in The Lancet Oncology.
-
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced Pascal Touchon, President and Chief Executive Officer of Atara, will present the Company’s 2023 accomplishments across strategic priorities and key upcoming milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11 at 9:45 a.m. PST / 12:45 p.m. EST.
-
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
1/8/2024
Atara Biotherapeutics, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registered direct offering to entities affiliated with an existing institutional investor.
-
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
Atara Biotherapeutics, Inc. announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, California.
-
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
12/20/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).
-
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
12/11/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate.
-
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.
-
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
11/29/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced positive new data for tabelecleucel (tab-cel® or EBVALLO™) in patients with relapsed or refractory (r/r) or treatment-naïve Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system (CNS) (EBV+ CNS PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
-
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
11/22/2023
Atara Biotherapeutics, Inc. announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.
-
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
11/10/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Tuesday, November 14, 2023 at 8:30 a.m. PST / 11:30 a.m. EST.
-
The allogeneic T-cell immunotherapy company is now approaching penny stock territory after its multiple sclerosis drug failed to reach the primary endpoint in a mid-stage study.
-
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
11/8/2023
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS).
-
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
11/1/2023
Atara Biotherapeutics Announces Expanded Global Tab-cel ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results.
-
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 06, 2023
10/6/2023
Atara Biotherapeutics, Inc. reported the grant of 56,750 restricted stock units of Atara’s common stock to four newly hired employees.
-
Pivotal clinical trials in Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis are expected to read out this fall. Here's a closer look.